Who is sponsoring NCT00790296?

NCT00790296 is sponsored by UConn Health.

What condition does NCT00790296 study?

NCT00790296 studies Cancer-related Fatigue.

What drugs are being tested in NCT00790296?

Interventions: Thyrotropin releasing hormone (TRH), Placebo.

What is the status of NCT00790296?

NCT00790296 is currently TERMINATED.

Last reviewed 2017-12-04 · How we verify

A Pilot, Randomized Double-Blind Placebo-Controlled Crossover Study of Synthetic Thyrotropin Releasing Hormone (TRH) Administration for the Treatment of Fatigue in Patients With Cancer

NCT00790296 Phase 2 TERMINATED Results posted

The primary objective of the study is to evaluate thyrotropin releasing hormone (TRH) as a treatment for cancer-related fatigue. The central hypothesis of this pilot study is that TRH is more efficacious than placebo in alleviating cancer-related fatigue in patients with breast or prostate cancer.

Details

Lead sponsor	UConn Health
Phase	Phase 2
Status	TERMINATED
Enrolment	11
Start date	2006-12
Completion	2010-03

Conditions

Cancer-related Fatigue

Interventions

Thyrotropin releasing hormone (TRH)
Placebo

Primary outcomes

Change in Visual Analog Scale for Energy (VAS-E)Score From Baseline to 7 Hrs Post Study Medication Infusion — Baseline and 7 hours post study medication infusion
1 to 100 scale with 1 referring to No Energy and 100 referring to Normal Energy.

Countries

United States